Loss of BAP1 protein expression is an independent marker of poor prognosis in patients with low-risk clear cell renal cell carcinoma. - Wikidata - wikimedia - TriplyDB

Loss of BAP1 protein expression is an independent marker of poor prognosis in patients with low-risk clear cell renal cell carcinoma.

Loss of BAP1 protein expression is an independent marker of poor prognosis in patients with low-risk clear cell renal cell carcinoma.

http://www.wikidata.org/entity/Q33821055

about

Loss of the deubiquitylase BAP1 alters class I histone deacetylase expression and sensitivity of mesothelioma cells to HDAC inhibitors.The roles of chromatin-remodelers and epigenetic modifiers in kidney cancer Cytoplasmic expression of BAP1 as an independent prognostic biomarker for patients with gliomas Comprehensive review of BAP1 tumor predisposition syndrome with report of two new cases Recurrence in Localized Renal Cell Carcinoma: a Systematic Review of Contemporary Data.Molecular genetics of clear-cell renal cell carcinoma The prognostic value of BAP1, PBRM1, pS6, PTEN, TGase2, PD-L1, CA9, PSMA, and Ki-67 tissue markers in localized renal cell carcinoma: A retrospective study of tissue microarrays using immunohistochemistry.Ambiguous melanocytic tumors with loss of 3p21.Intratumoral heterogeneity analysis reveals hidden associations between protein expression losses and patient survival in clear cell renal cell carcinoma.Bap1 is essential for kidney function and cooperates with Vhl in renal tumorigenesis Loss of PBRM1 and BAP1 expression is less common in non-clear cell renal cell carcinoma than in clear cell renal cell carcinoma.Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival.Prognostic value of carbonic anhydrase IX immunohistochemical expression in renal cell carcinoma: a meta-analysis of the literature.Sunitinib re-challenge in advanced renal-cell carcinoma.P2X7 receptor predicts postoperative cancer-specific survival of patients with clear-cell renal cell carcinoma.Immunohistochemistry Successfully Uncovers Intratumoral Heterogeneity and Widespread Co-Losses of Chromatin Regulators in Clear Cell Renal Cell Carcinoma.Decitabine induces G2/M cell cycle arrest by suppressing p38/NF-κB signaling in human renal clear cell carcinoma.BAP1 and PBRM1 in metastatic clear cell renal cell carcinoma: tumor heterogeneity and concordance with paired primary tumor.Loss of histone H3 lysine 36 trimethylation is associated with an increased risk of renal cell carcinoma-specific death New strategies in renal cell carcinoma: targeting the genetic and metabolic basis of disease.Decreased Expression of SETD2 Predicts Unfavorable Prognosis in Patients With Nonmetastatic Clear-Cell Renal Cell Carcinoma.Clear Cell Renal Cell Carcinoma: Associations Between CT Features and Patient Survival.Clear Cell Renal Cell Carcinoma Subtypes Identified by BAP1 and PBRM1 Expression.BAP1, PBRM1 and SETD2 in clear-cell renal cell carcinoma: molecular diagnostics and possible targets for personalized therapies.Uveal Melanoma Nuclear BRCA1-Associated Protein-1 Immunoreactivity Is an Indicator of Metastasis.What advances have been made in immune-therapy for renal cell carcinoma?Progression inference for somatic mutations in cancer.Prognostic role of BAP1 in pT1 clear cell carcinoma in partial nephrectomy specimens.Cancer associated missense mutations in BAP1 catalytic domain induce amyloidogenic aggregation: A new insight in enzymatic inactivation.Different prognostic roles of tumor suppressor gene BAP1 in cancer: A systematic review with meta-analysis.Application of the Stage, Size, Grade, and Necrosis (SSIGN) Score for Clear Cell Renal Cell Carcinoma in Contemporary Patients.Molecular profiling of renal cell carcinoma: building a bridge toward clinical impact.Precision medicine from the renal cancer genome.Imaging-genomic pipeline for identifying gene mutations using three-dimensional intra-tumor heterogeneity features.Lack of TMEM27 expression is associated with postoperative progression of clinically localized conventional renal cell carcinoma.High Expression of Colony-Stimulating Factor 1 Receptor Associates with Unfavorable Cancer-Specific Survival of Patients with Clear Cell Renal Cell Carcinoma.A BAP1 Mutation-specific MicroRNA Signature Predicts Clinical Outcomes in Clear Cell Renal Cell Carcinoma Patients with Wild-type BAP1.Malignant Mesothelioma, BAP1 Immunohistochemistry, and VEGFA: Does BAP1 Have Potential for Early Diagnosis and Assessment of Prognosis?Elevated Expression of N-Acetylgalactosaminyltransferase 10 Predicts Poor Survival and Early Recurrence of Patients with Clear-Cell Renal Cell Carcinoma.Multicenter Validation of Enhancer of Zeste Homolog 2 Expression as an Independent Prognostic Marker in Localized Clear Cell Renal Cell Carcinoma.

P2860

Q27853165-4C3B6FCE-5D7E-43E5-8DB2-8C97AE0ED128 Q28083152-AA5CD9DD-6532-4E7A-B126-2332D66F29F2 Q28383444-5130E477-CB41-4472-8039-0F8CAB109CF4 Q28397229-E1655F90-4C42-43D8-8139-66A5A50A4373 Q31163345-30190CD9-0707-43C4-9773-B1EF70BDC586 Q33729097-901E5FE0-1840-40B8-B6AB-3C84AF15CA18 Q33842185-F408C0F5-13FF-4800-8D40-0BF46FF549C8 Q33911349-A43D3D40-01B8-4A35-862B-D91D7809085B Q33913967-D34BB42F-478C-4BA6-BCE1-E195EEF02CBD Q34580977-FF43B24D-8BCE-4BE5-B657-D950C56074B1 Q34758616-2E981E7A-ECFB-475C-AC20-EB059AA06E1D Q34917972-0ED950FD-1D67-4BC4-9EA6-F2B5FB2F2E6A Q35451764-A811DDA0-6ADF-4C4D-955A-2C882F7860F0 Q35678358-3FA5FC0C-EA2E-4BE9-A4D9-4733F03D63B6 Q36092896-296B1472-7740-4B8D-9A3A-88C41F7992F2 Q36169098-D9BA10E0-8513-43B7-BF0E-05D1585016F2 Q36261661-1DD87658-2484-481D-AFFE-6A8AD3948BB0 Q36317488-0A623555-C59F-4296-8236-6FE2DB54689D Q36420712-57450384-7BD3-42BD-AE1C-3C0FE627E630 Q36696610-24C1DC56-FF39-48D4-9E1C-CD801768533E Q37016755-72089CB4-2A56-46E0-8654-7046A292D739 Q37172780-1E860C32-9FFB-4612-B518-EDAF91D1DF99 Q37573538-0925BD71-4B42-4A14-AAE6-48CABC8C4941 Q38545726-791D7291-FFB3-4329-A970-BC0AC8DAC5A4 Q38617242-945E07EC-4F4D-446D-A9DB-46CDF1535921 Q38759282-2BCD6AE2-6A84-40A6-B532-2A7048E993D1 Q38793244-C5D6E335-54DE-475C-BD0D-1DE52AC48352 Q38794945-914FB73C-0EA8-4217-BD83-BC444A7E113B Q38810854-F2614A44-873C-4C98-8356-88A7C3CDD9CC Q38843978-C742C1E7-1D13-422A-AA96-909ABEB9A25B Q38861806-2A8E2A44-CE46-4044-95DB-9D24B33E2FDF Q38910995-7DCB916F-5081-44C7-952E-C904A9C19919 Q38970282-DC047367-2935-4953-B978-2F0366F85A0F Q40028818-5F5B4C26-A141-4A21-A87E-C0742A2936CC Q40650893-7CAC39DC-74C3-4E76-804A-2920F855A2D9 Q41221347-B9996409-AB64-46AE-A2B0-5F99C0C48A8A Q41242139-8ED7CE51-5938-493A-B2B0-E7C2AEF4078E Q42728294-CE02B2A9-5A9C-4228-A7D0-FFCC0FF4F9D0 Q46773554-AEA45DC2-7ACA-4C19-B817-30EF5D370D3C Q47252459-6C4253AF-8BB2-4AF6-99A4-03186F87ACE7

P2860

Loss of BAP1 protein expression is an independent marker of poor prognosis in patients with low-risk clear cell renal cell carcinoma.

http://www.wikidata.org/entity/Q33821055

description

2013 nî lūn-bûn

@nan

2013 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Loss of BAP1 protein expressio ...... ear cell renal cell carcinoma.

@ast

Loss of BAP1 protein expressio ...... ear cell renal cell carcinoma.

@en

type

label

Loss of BAP1 protein expressio ...... ear cell renal cell carcinoma.

@ast

Loss of BAP1 protein expressio ...... ear cell renal cell carcinoma.

@en

prefLabel

Loss of BAP1 protein expressio ...... ear cell renal cell carcinoma.

@ast

Loss of BAP1 protein expressio ...... ear cell renal cell carcinoma.

@en

P1433

Q33821055-06D82386-4F42-479E-B0D6-46BA670249BA

P1476

Q33821055-6826E3A0-5F3B-4522-8A32-88FB4884BD5E

P2093

Q33821055-0EB2C9B6-E0C9-49C2-91AA-D282DC7DD971

Q33821055-4805528E-4749-4D11-9AE9-B95407FE0EC5

Q33821055-5140EE76-96DB-4A57-A2DB-48B245DF776F

Q33821055-56C92B0A-2497-4420-B9B0-6A382F270B30

Q33821055-71E5C5B3-2694-4F17-8971-2CAA70BEC388

Q33821055-823FEE23-2595-4F53-A04B-CF225C3FF600

Q33821055-96CD2CF3-DEFE-4447-88F4-D0FF50199B67

Q33821055-B9A44D7A-041C-43F1-94B9-EBCEFE9B60FC

Q33821055-CDB3A74F-FADB-438C-80E8-61AAADC526C5

P2860

Q33821055-096F4869-180D-46C0-BB54-776A18A66296

Q33821055-09BE06F7-34C4-405F-A341-3AD744073C1E

Q33821055-17538CC6-4E64-4EB5-9B09-4AB66A3E9A09

Q33821055-26DF83ED-2576-4AEA-825A-8747EC9DFB90

Q33821055-2F65A86E-7139-42AB-9C96-1CAB975CACFA

Q33821055-579BFD76-022C-43C9-ADBA-E173035D81F4

Q33821055-5D69819F-2C26-4EBE-8B65-E0B399A13B6A

Q33821055-6139F0CB-A2F4-4606-BDA5-65F5E7DE6863

Q33821055-6E8F42AD-5F2E-4700-A3AF-E96029608E3E

Q33821055-702C1CA7-9C98-4339-94A1-D411D8A45913

P304

Q33821055-61B49082-D38B-45AA-87EB-920091EB5223

P31

Q33821055-F3263199-10C2-433A-92A7-72610F34B5A8

P356

Q33821055-C68EDC0B-24E7-41B8-8BF9-19D5FB77091B

P407

Q33821055-240FE093-E58B-4C99-A4B8-8AA89F82CFE7

P433

Q33821055-6083DFC7-A5FD-4CAE-80F9-CAFD1B9382B5

P478

Q33821055-2AF0F85C-7C7E-40B4-9F27-5784798FFA78

P50

Q33821055-BDA0FFB4-7A9E-4084-84CD-FC2CF65EEB87

Q33821055-ED046C68-2988-4D16-9146-09397FCE2211

P577

Q33821055-C5717168-10F6-4FAE-83F8-0EB3ECCBD13F

P5875

Q33821055-CB2901BE-E9E7-4486-A3A4-38346B231437

P698

Q33821055-531475BB-3088-46C6-A453-EBC80FD28803

P932

Q33821055-30A62FFF-502C-468B-9204-2A4355B17001

P356

P1433

P1476

Loss of BAP1 protein expressio ...... ear cell renal cell carcinoma.

@en

P2093

Alexander Parker

http://www.w3.org/2001/XMLSchema#string

Daniel J Serie

http://www.w3.org/2001/XMLSchema#string

Dinesh Rakheja

http://www.w3.org/2001/XMLSchema#string

Eugene Frenkel

http://www.w3.org/2001/XMLSchema#string

James Brugarolas

http://www.w3.org/2001/XMLSchema#string

Jeanette E Eckel-Passow

http://www.w3.org/2001/XMLSchema#string

John C Cheville

http://www.w3.org/2001/XMLSchema#string

Mansi Parasramka

http://www.w3.org/2001/XMLSchema#string

Payal Kapur

http://www.w3.org/2001/XMLSchema#string

P2860

Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma

Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation.

Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network

Comprehensive molecular characterization of clear cell renal cell carcinoma.

Cancer statistics, 2013

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes

BAP1 loss defines a new class of renal cell carcinoma.

A novel germline mutation in BAP1 predisposes to familial clear-cell renal cell carcinoma.

Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma.

P304

1059-1067

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CNCR.28521

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

120

http://www.w3.org/2001/XMLSchema#string

P50

Richard W. Joseph

P577

2013-12-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

259536873

http://www.w3.org/2001/XMLSchema#string

P698

24382589

http://www.w3.org/2001/XMLSchema#string

P932

4075029

http://www.w3.org/2001/XMLSchema#string